NASDAQ:AUPH Aurinia Pharmaceuticals Q1 2026 Earnings Results & Report $16.65 +0.29 (+1.77%) As of 12:31 PM Eastern This is a fair market value price provided by Massive. Learn more. Aurinia Pharmaceuticals beat analyst expectations on both earnings and revenue in its Q1 2026 results, released May 7, 2026. The company reported EPS of $0.25 versus the $0.18 consensus estimate, while revenue of $77.71 million topped the $76.98 million estimate by $0.73 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 7, 2026TimeBefore Market OpensConference Call8:00 AM ET Aurinia Pharmaceuticals EPS ResultsActual EPS$0.25Consensus EPS $0.18Beat/MissBeat by +$0.07One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersAurinia Pharmaceuticals Revenue ResultsActual Revenue$77.71 millionExpected Revenue$76.98 millionBeat/MissBeat by +$731.00 thousandYoY Revenue GrowthN/AUpcoming EarningsAurinia Pharmaceuticals' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (6-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Quarterly report(10-Q) Aurinia Pharmaceuticals Q1 2026 Earnings FAQ Did Aurinia Pharmaceuticals beat earnings estimates for Q1 2026? Aurinia Pharmaceuticals (NASDAQ:AUPH) reported earnings of $0.25 per share for Q1 2026, beating the consensus estimate of $0.18. The report was announced on Thursday, May 7, 2026. What was Aurinia Pharmaceuticals' revenue for Q1 2026? Aurinia Pharmaceuticals reported revenue of $77.71 million for Q1 2026, against a consensus estimate of $76.98 million. When is Aurinia Pharmaceuticals' next earnings date? Aurinia Pharmaceuticals' next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for Aurinia Pharmaceuticals on the company's earnings history page. Aurinia Pharmaceuticals Earnings HeadlinesAUPH - Aurinia Pharmaceuticals Inc.October 8, 2026 | seekingalpha.comCould Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?August 28, 2026 | finance.yahoo.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 14 at 1:00 AM | Awesomely (Ad)AUPH stock rallies 6% after-hours — here’s whyAugust 19, 2026 | msn.comAurinia Settles Patent Litigation with TevaAugust 19, 2026 | financialpost.comFAurinia, Teva Reach Voclosporin Patent Litigation SettlementAugust 19, 2026 | tipranks.comSee More Aurinia Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aurinia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aurinia Pharmaceuticals and other key companies, straight to your email. Email Address About Aurinia PharmaceuticalsAurinia Pharmaceuticals (NASDAQ:AUPH). is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s primary product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with background immunosuppressive therapy to treat adult patients with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus. Lupkynis was approved by the U.S. Food and Drug Administration in 2021 and subsequently authorized in Canada. Aurinia markets the therapy primarily in North America and supports patients through commercial, medical, and patient-assistance programs. The company has also conducted research into additional autoimmune and kidney-related applications for its technology. Headquartered in Edmonton, Alberta, Aurinia was formerly known as Isotechnika Pharma before adopting its current name in 2013. The company has operated as a publicly traded biotechnology business focused on advancing treatments for patients with significant unmet medical needs.View Aurinia Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Don’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based Strength Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
